dc.contributor.author
Gomez Lara, Josep
dc.contributor.author
Oyarzabal, Loreto
dc.contributor.author
Ortega Paz, Luis
dc.contributor.author
Brugaletta, Salvatore
dc.contributor.author
Romaguera, Rafael
dc.contributor.author
Salvatella, Neus
dc.contributor.author
Roura i Ferrer, Gerard
dc.contributor.author
Rivero, Fernando
dc.contributor.author
Fuentes, Lara
dc.contributor.author
Alfonso, Fernando
dc.contributor.author
Otaegui, Imanol
dc.contributor.author
Vandeloo, Bert
dc.contributor.author
Vaquerizo, Beatriz
dc.contributor.author
Sabate, Manel
dc.contributor.author
Comín Colet, Josep
dc.contributor.author
Gomez Hospital, Joan Antoni
dc.date.issued
2021-12-09T08:50:32Z
dc.date.issued
2021-12-09T08:50:32Z
dc.date.issued
2021-11-03
dc.date.issued
2021-12-02T08:33:39Z
dc.identifier
https://hdl.handle.net/2445/181700
dc.description.abstract
Background Early generation drug-eluting stents (DESs) showed a high grade of coronary endothelial dysfunction that was attributed to lack of stent reendothelialization. Endothelium-dependent vasomotor response of current DESs and bioresorbable scaffolds (BRSs) remains unknown. This study sought to assess the device-related endothelial function of current devices and to correlate neointima healing with endothelial function. Methods and Results A total of 206 patients from 4 randomized trials treated with the durable-polymer everolimus-eluting Xience (n=44), bioresorbable-polymer sirolimus-eluting Orsiro (n=35), polymer-free biolimus-eluting Biofreedom (n=24), bioactive endothelial-progenitor cell-capturing sirolimus-eluting Combo DES (n=25), polymer-based everolimus-eluting Absorb (n=44), and Mg-based sirolimus-eluting Magmaris BRS (n=34) underwent endothelium-dependent vasomotor tests and optical coherence tomography imaging, as per protocol, at follow-up. Crude vasomotor responses of distal segments to low-dose acetylcholine (10-6 mol/L) were different between groups: bioresorbablepolymer DEShad the worst (-8.4%±12.6%) and durable-polymer DES had the most physiologic (-0.4%±11.8%; P=0.014). High-dose acetylcholine (10-4 mol/L) showed similar responses between groups (ranging from -10.8%±11.6% to -18.1%±15.4%; P=0.229). Device healing was different between devices. Uncovered struts ranged from 6.3%±7.1% (bioresorbable-polymer DES) to 2.5%±4.5% (bioactive DES; P=0.056). In multivariate models, endothelium-dependent vasomotor response was associated with age, bioresorbable-polymer DES, and angiographic lumen loss, but not with strut coverage nor plaque type. Endothelial dysfunction (defined as ≥4% vasoconstriction) was observed in 46.6% of patients with low-dose and 68.9% with high-dose acetylcholine, without differences between groups. Conclusions At follow-up, endothelial dysfunction was frequently observed in distal segments treated with current stents without remarkable differences between devices. Although neointima healing was different between devices, poor healing was not associated with endothelial dysfunction.
dc.format
application/pdf
dc.publisher
Ovid Technologies (Wolters Kluwer Health)
dc.relation
Reproducció del document publicat a: https://doi.org/10.1161/JAHA.121.022123
dc.relation
Journal of the American Heart Association, 2021, vol. 10, num. 22
dc.relation
https://doi.org/10.1161/JAHA.121.022123
dc.rights
cc by-nc (c) Gomez Lara, Josep et al, 2021
dc.rights
http://creativecommons.org/licenses/by-nc/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject
Malalties vasculars
dc.subject
Cirurgia cardiovascular
dc.subject
Peripheral vascular diseases
dc.subject
Cardiovascular surgery
dc.title
Coronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion